Hims & Hers stock poised for heavy losses after quick U-turn on plan for oral Wegovy competitor
Author


Hims & Hers stock tumbled in early action on Monday after the U.S. company quickly reversed plans to introduce its own version of Novo Nordisk’s Wegovy oral weight-loss drug.

You May Also Like

Treasury yields slip as U.S. recession talk lingers

Bond yields fell early Monday after U.S. President Donald Trump did not…
Eagles star A.J. Brown sends self-help book ‘Inner Excellence’ from 523,497th place to No. 1 on Amazon

Eagles star A.J. Brown sends self-help book ‘Inner Excellence’ from 523,497th place to No. 1 on Amazon

While Tom Brady and author Jim Murphy were surprised to see Brown…

Canary Wharf credit rating cut deeper into junk by Fitch

Canary Wharf Group’s credit has been cut further into junk territory by…
The $7,500 federal EV tax credit is on the ballot in November

The $7,500 federal EV tax credit is on the ballot in November

As Donald Trump made his victory speech after Iowa’s caucuses, the front-runner…